Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2006-07-25
2006-07-25
Hartley, Michael G. (Department: 1618)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C424S009100
Reexamination Certificate
active
07081238
ABSTRACT:
A method of diagnosing attention deficient-hyperactivity disorder (ADHD) in a human patient by assessing the level of dopamine transporter in at least one region of the patient's central nervous system, where an elevated level of dopamine transporter in the patient is indicative of ADHD. In embodiments of the invention, assessment of dopamine transporter levels includes assessing binding of a dopamine transporter ligand to the dopamine transporters using PET or SPECT.
REFERENCES:
patent: 3813404 (1974-05-01), Clarke et al.
patent: 5493026 (1996-02-01), Elmaleh et al.
patent: 5496953 (1996-03-01), Kuhar et al.
patent: 5500343 (1996-03-01), Blum et al.
patent: 5621133 (1997-04-01), DeNinno et al.
patent: 5760055 (1998-06-01), Davies
patent: 5770180 (1998-06-01), Madras et al.
patent: 5874090 (1999-02-01), Baker et al.
patent: 5902797 (1999-05-01), Bell et al.
patent: 6008227 (1999-12-01), Davies et al.
patent: 6011070 (2000-01-01), Froimowitz et al.
patent: 6350758 (2002-02-01), Kozikowski et al.
patent: 6358492 (2002-03-01), Kuhar et al.
patent: 6531483 (2003-03-01), Kuhar et al.
patent: WO94/04146 (1994-03-01), None
patent: WO97/16210 (1997-05-01), None
patent: WO97/40859 (1997-11-01), None
patent: WO 98/24788 (1998-06-01), None
patent: WO 99/07359 (1999-02-01), None
Ernst et al., “High Midbrain [′° F.]DOPA Accumulation in Children With Attention Decifict Hyperaeractivi Disorder”, Am J Psychiatry, 156:8, Aug. 1999.
Ernst et al., “DOPA Decarboxylase Activity in Attention Deficit Hyperactivity Disorder Adults. A|Fluorine-18 Fluorodopa Positron Emission Tomographic Study”, The Journal of Neuroscience,Aug. 1, 1998, 18(15):5901-5907.
Arnold et al., “National Institute of Mental Health Collaborative Multimodal Treatment. Study ofChildren with ADHD (the MTA). Design Challenges and Choices,” Arch. Gen. Psychiatry,54(9):865-70(1997).
Babich et al., “C-11 Methyl-3p-[4-fluorophenyl]-N-iodo-E-allyl-1aH-5aH-nortropane-2(3carboxylate: a bi ghlyselective DAT ligand for PET,” J. Nuclear Medicine, 39:238 (1998).
PCT search report, application No. PCT/US00/17769, international filing date Jun. 28, 2000, mailed Nov. 14, 2000.
Madras et al., “Imaging the Dopamine Transporter: A Window on Dopamine Neurons. Advances inNeurodegenerative Disorders,” J. Marwab, H. Teitelbaum, Eds., vol. 1. Parkinson's Disease, pp. 229-253(1998).
Meltzer, et al., “Substituted 2-Phenyltropane Analogs of Cocaine; Synthesis, Inhibition of Binding at Cocaine Recognition Sites and Positron Emission Tomography (PET) Imaging,” J. Med. Chem., 36:855-862(1993).
Sano et al., “A 40-Nucleotide Repeat Polymorphism in the Human Dopamine Transporter Gene,”Hum. Genet., 91:405-406 (1993).
Seeman et al., “Anti-Hyperactivity Medication: Methylphenidate and Amphetamine,” Mol.Psychiatry, 3(5):386-96 (1998).
Thapar et al., “Genetic Basis of Attention Deficit and Hyperactivity,” Br. J. Psychiatry, 174:105-11(1999).
Volkow et al., “Dopamine Transporter Occupancies in the Human Brain Induced by TherapeuticDoses of Oral Meth yl-phenidate,” Am. J. Psychiatry, 155:1325-31 1998).
Waldman et al., “Association and Linkage of the Dopamine Transporter Gene and Attention-DeficitHyperactivity Disorder in Children: Heterogeneity Owing to Diagnostic Subtype and Severity,” Am. J. Hum. Genet, 639(6):1767-76 1998).
Wilens et al., “The Stimulants,” Psychiatr. Clin North Am., 15(1):191-222 (1992).
Bonab et al., “Determination of Dopamine Transporter. Density and Affinity Using High and LowSpecific Activity Injections of C-11 Altro ane,” J. Nuclear Medicine, 39:66 (1998).
Bonab et al., “Estimation of C-11-CFT Binding Potential by Iterative Fitting (IF) and Comparisonwith Reference Region Graphical (RRG) and Reference Fitting (RF) in Monkeys, ”J. Nuclear, May 1998.
Canfield et al., “Autoradiographic Localization of Cocaine Binding Sites by [3H]CFT ([3H]WIN35,428) in the Monkey Brain,” Synapse, 6(2):189-95 (1990).
Comings et al., “Polygenic Inheritance of Tourette Syndrome, Stuttering, Attention DeficitHyperactivity, Conduct, and Oppositional Defiant Disorder: The Additive and Substractive Effectof the Three Dopaminergic Genes—DRD2, D beta H, and DAT1,” Am. J. Med. Genet, 67(3):26488(1996).
Cook et al., “Association of Attention-Deficit Disorder and the Dopamine Transporter Gene,” Am. J.Hum. Genet., 56(4):993-8 (1995).
Daly et al., “Mapping Susceptibility Loci in Attention Deficit Hyperactivity Disorder: PreferentialTransmission of Parental Alleles at DAT1, DBH and DRD5 to Affected Children,” Mol. Psychiatry,4(2):192-6 1999).
Fischman et al., “SPECT Imaging of Dopamine Transporter Sites in Normal and MPTP-TreatedRhesus Monkeys,” J. Nuclear Medicine, 38(1):144-50 1997.
Fischman et al., “Rapid Detection of Parkinson's Disease with Altropane, a SPECT Ligand,”Synapse, 29:128-41 1998).
Gill et al., “Confirmation of Association Between Attention Deficit Hyperactivity Disorder and aDopamine Transporter Polymorphism,” Mol. Psychiatry, 2(4):311-3 (1997).
Greenhill et al., “Stimulant Medications,” J. Am. Acad. Child Adolesc. Psychiatry, 38(5):503-12(1999).
Kaufman et al., “Distribution of Cocaine Recognition Sites in Monkey Brain: 1. In Vitro Autiography with [3h]CFT, ”SYNAPSE, 9(3):177-87 (1991).
Madras et al., “Technepine: A High-Affinity 99m-Technetium Probe to Label the DopamineTransporter in Brain b SPECT Imaging,” Synapse, 22(3):239-46 (1996).
Madras et al., “N-Modified Fluorophenyltropane Analogs of Cocaine with High Affinity for CocaineReceptors,” Pharmacol. Biochem. Behav., 35(4):949-53 1990.
Madras et al., “Effects of Cocaine and Related Drugs in Nonhuman Primates. 1. [3H]CocaineBinding Sites in Caudate-Putamen,” J. Pharmacol. Ex p. Ther., 251(1):131-41 (1989).
Madras et al., “[″′1]Altropane, a SPECT Imaging Probe for Dopamine Neurons: 1. DopamineTransporter Binding in Nonhuman Primate Brain,” Synapse, 29:93-104 1998).
Madras et al., “[″′1]Altropane, a SPECT Imaging Probe for Dopamine Neurons: II. In Vitro and ExVivo Distribution in Primate Brain,” Synapse, 29:105-115 (1998).
Madras et al., “[r'71]Altropane, a SPECT Imaging Probe for Dopamine Neurons: III. HumanDopamine Transporter in Post-Mortem Normal and Parkinson's Diseased Brain,” Synapse, 29:116127(1998).
Krause et al., “Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomgrapyh”, Neuroscience Letters 285 (2000) 107-110.
Krause et al., Attention deficit hyperactivity disorder: binding of [99M/Tc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment.
Zametkins, M.D.; and Wendi Liotta “The Neurobiology of Attention-Deficit/Hyperactivity Disorder” J Clin Psychiatry 1998;59 (suppl 7).
Bertha K. Madras, et al.,The Dopamine Transporter: Relevance To Attention Deficit Hyperactivity Disorder(ADHD), Behavioural Brain Research, vol. 130 (2002) pp. 57-63.
Biederman et al, “High Risk for attention Deficit Hyperactivity Disorder Among Children of Parents with Childhood Onset of the Disorder: A Pilot Study,” Am. J. Psychiatry, 152(3):431-35 (1995).
Madras et al., “Imaging the Dopamine Transporter: A Window on Dopamine Neurons. Advances in Neurodegenerative Disorders,” J. Marwah, H. Teitelbaum, Eds., vol. 1. Parkinson's Disease, pp. 229-253 (1998).
Meltzer, et al., “Substituted 2-Phenyltropane Analogs of Cocaine; Synthesis, Inhibition of Binding at Cocaine Recognition Sites and Positron Emission Tomography (PET) Imaging,” J. Med. Chem., 36:855-862 (1993).
Sano et al., “A 40-Nucleotide Repeat Polymorphism in the Human Dopamine Transporter Gene,
Fischman Alan J.
Madras Bertha K.
Meltzer Peter C.
Edwards Angell Palmer & & Dodge LLP
Hartley Michael G.
Neuner George W.
Organix Inc.
Russett Mark D.
LandOfFree
Methods for diagnosing and monitoring treatment ADHD by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for diagnosing and monitoring treatment ADHD by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosing and monitoring treatment ADHD by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3575708